These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26963505)

  • 1. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of a silicone elastomer vaginal ring as potential microbicide delivery method in African women: A Phase 1 randomized trial.
    Nel A; Martins J; Bekker LG; Ramjee G; Masenga G; Rees H; van Niekerk N
    PLoS One; 2018; 13(5):e0196904. PubMed ID: 29813074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.
    Chen BA; Zhang J; Gundacker HM; Hendrix CW; Hoesley CJ; Salata RA; Dezzutti CS; van der Straten A; Hall WB; Jacobson CE; Johnson S; McGowan I; Nel AM; Soto-Torres L; Marzinke MA;
    Clin Infect Dis; 2019 Mar; 68(7):1144-1151. PubMed ID: 30289485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
    Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
    Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
    N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
    BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
    Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
    AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
    Liu AY; Dominguez Islas C; Gundacker H; Neradilek B; Hoesley C; van der Straten A; Hendrix CW; Beamer M; Jacobson CE; McClure T; Harrell T; Bunge K; Devlin B; Nuttall J; Spence P; Steytler J; Piper JM; Marzinke MA;
    J Int AIDS Soc; 2021 Jun; 24(6):e25747. PubMed ID: 34118115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
    Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
    PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
    Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
    J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS
    J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
    Baeten JM; Palanee-Phillips T; Brown ER; Schwartz K; Soto-Torres LE; Govender V; Mgodi NM; Matovu Kiweewa F; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Pather A; Naidoo L; Husnik M; Richardson BA; Parikh UM; Mellors JW; Marzinke MA; Hendrix CW; van der Straten A; Ramjee G; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Mayo A; Scheckter R; Berthiaume J; Livant E; Jacobson C; Ndase P; White R; Patterson K; Germuga D; Galaska B; Bunge K; Singh D; Szydlo DW; Montgomery ET; Mensch BS; Torjesen K; Grossman CI; Chakhtoura N; Nel A; Rosenberg Z; McGowan I; Hillier S;
    N Engl J Med; 2016 Dec; 375(22):2121-2132. PubMed ID: 26900902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.